Relmada Therapeutics shares are trading higher after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. Also, the company announced a $160 million private placement.

LABD

<p>Relmada Therapeutics shares are trading higher after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. Also, the company announced a $160 million private placement.</p>

benzinga_article

Direxion S&P Biotech Bear 3X

iShares US Pharma

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Relmada Therapeutics

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

News